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Using a hepatitis B virus (HBV) transgenic mouse model, 
we previously showed that a single dose of double-
stranded adeno-associated virus (dsAAV) vector sero-
type 8 carrying a small hairpin RNA (shRNA) effectively 
reduces HBV replication and gene expression, but the 
effect gradually decreases with time. In this report, we 
compared the anti-HBV RNA interference (RNAi) effect 
of dsAAV8 with those of dsAAV7 and dsAAV9, two other 
hepatotropic AAV vectors, and examined whether the 
sequential use of these heterologous AAV vectors could 
prolong the anti-HBV effect. Our results showed that 
shRNA delivered by each of the three dsAAV vectors 
profoundly reduced the serum HBV titer and liver HBV 
mRNA and DNA levels in the transgenic mice for up to 
22 weeks, with dsAAV8 having the greatest inhibitory 
effect, followed by dsAAV9 and dsAAV7. The potency of 
dsAAV8 correlated with the presence of higher levels of 
vector DNA and anti-HBV shRNA in the liver. An in vivo 
cross-administration experiment showed that preexist-
ing anti-AAV8 antibody completely blocked the anti-HBV 
RNAi effect of dsAAV8, but had no effect on the potency 
of dsAAV7 and dsAAV9. Moreover, we demonstrated 
that a longer anti-HBV effect could be achieved by the 
sequential use of dsAAV8 and dsAAV9. These results indi-
cate that effective and persistent HBV suppression might 
be achieved by a combination of the power of RNAi 
silencing effect and multiple treatments with different 
AAV serotypes.
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IntroductIon
Hepatitis B virus (HBV) infection remains a serious infectious 
disease, resulting in ~350 million chronically infected patients 
worldwide. Patients chronically infected with HBV suffer from 
liver complications, including cirrhosis and hepatocellular carci-
noma, leading to >1 million deaths every year.1,2 Recent reports 
have revealed that the incidence of hepatocellular carcinoma in 
chronic HBV patients is positively correlated with HBV titer and 
HBeAg expression level.3,4 Accordingly, the final goal for chronic 
HBV therapy is to achieve long-term HBV suppression, thus pre-
venting the progression of liver diseases. Current anti-HBV thera-
pies include immunomodulators, such as interferon-α-2a and 
PEGylated interferon-α-2b, as well as nucleoside and nucleotide 
analogs, such as lamivudine, adefovir dipivoxil, entecavir, which 
inhibit HBV reverse transcriptase and thus viral  replication.5 
However, these anti-HBV drugs have limited effectiveness in com-
pletely eliminating the virus, leading to selection of drug-resistant 
mutations and a high rate of relapse when treatment is discon-
tinued.6 Thus, the development of new treatment strategies for 
chronic HBV remains a major medical challenge.
RNA interference (RNAi) is an evolutionary conserved mech-
anism in which gene expression is inhibited through mRNA 
degradation using small RNA fragments with completely com-
plementary sequences to the mRNA being degraded. There are 
ample reports demonstrating that RNAi has great potential as a 
new therapeutic agent for infectious diseases.7–9 In terms of HBV 
 infection, early in vitro studies provided proof-of-principle that 
synthetic small interfering RNA (siRNA) or plasmid-encoded 
small hairpin RNA (shRNA) can effectively repress viral replica-
tion and gene expression.10–13 The in vivo anti-HBV effect of RNAi 
was initially evaluated in animal models established by hydrody-
namic co- injection of HBV expression plasmids and anti-HBV 
siRNA or shRNA expression plasmids.11,14 Moreover, the in vivo 
anti-HBV effect can be enhanced by chemical modification and 
lipid- encapsulation of siRNAs.15,16 However, because of the tran-
sient nature of the suppression and the inefficient delivery of these 
approaches, synthetic siRNAs and plasmid-encoded shRNAs are 
unlikely to have durable anti-HBV effects in more stringent HBV 
infection conditions, such as in HBV transgenic mice or in chroni-
cally infected HBV patients, as virtually all hepatocytes are infected 
in these subjects. In this regard, the use of a shRNA-expressing viral 
vector, which can achieve efficient and uniform transduction of all 
liver cells to produce a more sustained RNAi effect, represents an 
attractive approach to the treatment of chronic HBV infection.
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Adeno-associated virus (AAV), with an excellent safety pro-
file and effectiveness of in vivo transgene expression, has gained 
popularity in gene therapy applications over the past decade.17,18 
Several preclinical studies have revealed that AAV serotype 8 is 
particularly efficient in transducing the liver.19–22 In our previous 
study,23 we developed several shRNA-expressing double-stranded 
AAV2/8 vectors (dsAAV8) to deliver anti-HBV shRNAs and eval-
uated their therapeutic efficacy in a HBV transgenic mouse model, 
which produces up to 1 × 109 viral genomes in the  circulation, 
comparable to that found in chronic HBV patients. We showed 
that a single injection of the dsAAV8 vector, carrying one par-
ticular HBV-specific shRNA, had a potent suppressive effect that 
almost completely depleted HBV replication in the liver, leading 
to an up to 3 log10 decrease in HBV load in the circulation, and 
that this inhibitory effect lasted for up to 4 months without appar-
ent toxicity. Nevertheless, the RNAi-mediated HBV suppressive 
effect slowly decreased with time, accompanied by a gradual loss 
of the AAV genome in the mouse liver.
In this study, we compared the anti-HBV RNAi effect of dsAAV8 
with those of two recently isolated AAV serotypes, dsAAV7 and 
dsAAV9, which also show high liver transduction efficiency.19,24 
We also examined whether repeated injections of different AAV 
serotypes carrying shRNA could extend the duration of the anti-
HBV effect. The multiple treatment strategy was designed based on 
several previous reports that repeated administration of immuno-
logically distinct AAV serotypes can successfully prolong transgene 
expression and increase its levels.25–27
results
comparison of liver transduction efficiency  
of dsAAV7, dsAAV8, and dsAAV9
On the basis of previous reports, which demonstrated a remark-
able tropism of AAV7, AAV8, and AAV9 for the liver,19,24 we chose 
these three dsAAV serotypes to deliver shRNA for HBV treatment. 
For a direct comparison of these vectors in liver gene delivery, we 
prepared AAV vectors containing an identical AAV2-based DNA 
cassette containing the green fluorescent protein (GFP) gene driven 
by a constitutive CMV enhancer/β-actin (CB) promoter. Since the 
AAV2 genome was designed to include a deletion in the terminal 
resolution site in one end of the inverted terminal repeat, the final 
AAV vectors contained double-stranded genomes. These vec-
tors were designated as dsAAV7/CB-GFP, dsAAV8/CB-GFP, and 
dsAAV9/CB-GFP. Wild-type ICR mice were intravenously (IV) 
injected with 1 × 1012 vector genomes (vg) per mouse of one of the 
vectors and killed 3 weeks later to analyze GFP expression in the 
liver by fluorescence microscopy. As shown in Figure 1a, injec-
tion with each of the three dsAAV serotypes resulted in high GFP 
expression in the mouse liver. Interestingly, dsAAV8 and dsAAV9 
gave a relatively uniform GFP distribution in the liver, whereas 
dsAAV7 transduction was essentially confined to the centrilobu-
lar region. Quantification of the fluorescence intensity revealed 
that the dsAAV8 vector gave the highest level of GFP expression, 
resulting in 3.6- or 6.6-fold greater fluorescence intensity than 
that obtained with the dsAAV9 or dsAAV7 vector, respectively 
(Figure 1b, upper panel). Calculation of the percentage of the total 
area that contained GFP-positive cells showed a similar pattern of 
transduction ability of these three dsAAV  vectors, with ~65% of 
hepatocytes being infected by dsAAV8, significantly higher than 
the 50 and 34% transduction rate achieved using dsAAV9 and 
dsAAV7, respectively (Figure 1b, lower panel). These results dem-
onstrate that, of the three liver-tropic vectors examined, dsAAV8 
was the most efficient in directing liver gene transfer.
comparison of the efficacy of the different dsAAV 
serotypes in shrnA-mediated HBV suppression
To investigate the relative efficacy of the three dsAAV serotypes 
in shRNA-based anti-HBV therapy, we selected HBV-S1 shRNA 
to construct the pseudotyped dsAAV vectors. Our previous 
study showed that HBV-S1, but not other HBV-specific shRNAs, 
effectively suppressed HBV replication and gene expression in 
the ICR/HBV transgenic mouse model.23 In this study, we used 
groups of HBV transgenic mice with serum HBV DNA > 5 × 107 
genome copies/ml which were IV injected with 1 × 1012 vg per 
mouse (or ~3.3 × 1013 vg/kg) of dsAAV7, dsAAV8, or dsAAV9 
vector expressing HBV-S1 or an irrelevant GL2 shRNA to assess 
the efficacy of RNAi in vivo. Figure 2a shows serum HBV titers in 
each group 2 weeks after dsAAV administration. All the HBV-S1 
shRNA-encoding vectors markedly reduced the serum HBV titer 
(Figure 2a). dsAAV8/HBV-S1 had the strongest anti-HBV effect, 
reducing the serum HBV titer by an average of 2,380-fold. dsAAV7/
HBV-S1 and dsAAV9/HBV-S1 were equivalent in HBV suppres-
sion, resulting in an average 710- and 800-fold reduction in serum 
HBV titer, respectively. For all three serotypes, the dsAAV vectors 
expressing the unrelated GL2 shRNA did not significantly reduce 
the HBV titer. Figure 2b shows the time course of the inhibitory 
effect of the three different dsAAV/HBV-S1 serotypes. All dsAAV 













































Figure 1 comparison of liver transduction efficiency of different 
double-stranded adeno-associated virus (dsAAV) serotypes. Groups 
of ICR mice were intravenously injected with 1 × 1012 vector genomes 
per mouse of dsAAV7/CB-GFP, dsAAV8/CB-GFP, or dsAAV9/CB-GFP 
vector. (a) Photographs of liver cryosections (5 μm) were taken 3 weeks 
after injection and examined for green fluorescent protein (GFP) expres-
sion. Original magnification ×40. Bar = 500 μm. (b) Quantification of 
the average fluorescence intensity and the percentage of the total area 
containing GFP-positive cells.
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dsAAV treatment, with peak inhibition at weeks 3 and 4, followed 
by a slow recovery of the HBV titer over the next 4 months. At the 
end of the observation period (22 weeks after dsAAV administra-
tion), significant suppression was still seen in mice treated with all 
dsAAV serotypes, with dsAAV8/HBV-S1 yielding the best inhibi-
tion (190-fold reduction in serum HBV titer compared to the 11- 
and 18-fold reduction using the dsAAV7/HBV-S1 and dsAAV9/
HBV-S1 vectors, respectively).
We then measured levels of liver HBV RNA and DNA in 
dsAAV/HBV-S1-injected mice by northern and Southern blot 
analysis of samples obtained 12 weeks after vector injection. 
Northern blots showed that, consistent with the serum HBV 
titer results, treatment with dsAAV8/HBV-S1 led to the great-
est decrease in HBV mRNA levels (Figure 3a). Compared to 
the saline-treated control, dsAAV8/HBV-S1 resulted in an 
average 83% reduction in the steady levels of both the 3.5- and 
2.4/2.1-kb HBV transcripts when normalized to the expression 
level of endogenous glyceraldehyde 3-phosphate dehydroge-
nase mRNA. A significant reduction in HBV mRNA levels was 
also seen in dsAAV7/HBV-S1- and dsAAV9/HBV-S1-treated 
mice, but this was lower than in dsAAV8-treated mice, with a 
respective 53 and 55% reduction in the levels of the 3.5- and 
2.4/2.1-kb  transcripts for the dsAAV7 vector and a 55 and 64% 
reduction for the dsAAV9 vector. Southern blot analysis showed 
that dsAAV-delivered HBV-S1 shRNA had a more pronounced 
effect on HBV replicative DNA levels than mRNA transcripts 
levels. In the dsAAV8/HBV-S1-treated mice, relaxed circular 
and single-stranded linear viral DNA were virtually undetect-
able (>97% reduction compared to the saline group). dsAAV7/
HBV-S1 and dsAAV9/HBV-S1 also showed a significant reduc-
tion in liver HBV DNA levels, with an average 94% reduction for 
both vectors.
To examine whether the different RNAi efficacies of the 
three different dsAAV serotypes correlated with their gene 
transfer efficiency, we performed Southern blot analysis to eval-
uate the amount of vector DNA in the liver. DNA samples were 
digested with HindIII and XbaI to excise an internal  fragment 
of 1.05 kb and hybridized with a probe corresponding to the 
GFP sequence, which present in all the dsAAV vectors. As 
shown in Figure 4a, dsAAV8/HBV-S1-injected mice had the 
highest amounts of vector DNA in the liver (25 ± 10 copies per 
cell). Administration of the same dose of dsAAV7 or dsAAV9 
resulted in, respectively, an average of 7.6 ± 4 or 13 ± 2 copies 


















0 1 2 3 4 6 8 10
Week after injection




















Figure 2 comparison of different double-stranded adeno-associated 
virus (dsAAV) serotypes in small hairpin rnA (shrnA)-mediated 
hepatitis B virus (HBV) suppression. Groups of HBV transgenic mice 
(n = 4–6) were intravenously injected with 1 × 1012 vector genomes per 
mouse of dsAAV7, dsAAV8, or dsAAV9 vector expressing control GL2 or 
HBV-S1 shRNAs. (a) Two weeks after injection, serum HBV titers were 
measured by real-time PCR and are presented as a percentage of the 
pretreatment titer for the group (mean ± SD). (b) Time course of HBV 
suppression after injection of the different dsAAV serotypes encoding 
HBV-S1 shRNA (mean ± SD).









Figure 3 reduction in liver hepatitis B virus (HBV) mrnA and dnA 
levels in transgenic mice by the different double-stranded adeno-
associated virus (dsAAV) serotypes. HBV transgenic mice were treated 
with the different dsAAV serotypes expressing HBV-S1 small hairpin RNA 
as described in the legend of Figure 2, then, 12 weeks after injection, 
liver samples were collected for northern and Southern blot analysis. 
(a) Northern blot analysis of HBV 3.5-, 2.4-, and 2.1-kb mRNAs, with 
mouse glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA as 
the internal control. (b) Southern blot analysis of HBV DNA. The bands 
corresponding to the integrated transgene (Tg) and the HBV replicative 
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Figure 4 copy number of the different double-stranded adeno-
associated virus (dsAAV) serotype vectors and small hairpin rnA 
(shrnA) expression in the liver. Liver samples were obtained from the 
dsAAV-treated hepatitis B virus (HBV) transgenic mice as described in the 
legend of Figure 2. (a) Analysis of dsAAV vector genomes. Total liver 
DNA (10 μg) from mice treated with the different dsAAV serotypes was 
analyzed by Southern blotting after BamHI and XbaI digestion, which 
releases the 1.05-kb fragment from the AAV genome. The vector plas-
mid was used as the reference standard for estimation of AAV genome 
copy number. (b) Total liver RNA (30 μg) was analyzed by northern blot-
ting using radiolabeled probes specific for the antisense strand of HBV-S1 
shRNA (“as HBV-S1”) and endogenous microRNA-122.
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Next we measured expression levels of the antisense strand 
of the processed HBV-S1 shRNA in the liver by northern blot 
analysis using a specific isotope-labeled oligonucleotide probe. 
Consistent with the result of the AAV vector DNA analysis, mice 
injected with dsAAV8/HBV-S1 expressed 1.43- or 1.35-fold more 
HBV-S1 than mice injected with the dsAAV7 or dsAAV9 vector, 
respectively (Figure 4b, upper panel). A recent report showed 
that overexpression of shRNAs in mouse liver by dsAAV vectors 
can lead to hepatotoxicity, which is probably due to competi-
tion and interference with endogenous microRNA biogenesis.28 
To determine whether endogenous microRNA expression was 
affected in our RNAi-treated mice, the membrane was stripped 
and rehybridized to detect microRNA-122, which is known to 
be specifically expressed in the liver. We found that endogenous 
microRNA-122 expression in dsAAV/HBV-S1-treated mice was 
indistinguishable from that in the saline control animals, or even 
slightly increased (15–25% increase) (Figure 4b, lower panel). 
These results clearly show that significant anti-HBV inhibition 
can be achieved by shRNA-expressing dsAAV vectors without 
affecting microRNA expression and that the HBV inhibitory 
effect is mainly determined by the different liver transduction 
rates of the three dsAAV serotypes.
HBV suppression by sequential delivery of shrnAs 
using serologically distinct dsAAV serotypes
To determine whether sequential delivery of shRNAs by the 
dsAAV7, dsAAV8, and dsAAV9 vectors was possible, we first dem-
onstrated that there was minimal immune cross-reactivity between 
dsAAV7, dsAAV8, and dsAAV9 by an in vitro neutralization assay 
(Supplementary Figure S1 and Supplementary Materials and 
Methods). Next, we designed an animal experiment to determine 
the RNAi effect of the second injection and examine possible cross-
reactivity of these dsAAV vectors in vivo. HBV transgenic mice 
were first injected with 1 × 1012 vg per mouse of dsAAV8/GL2, 
and then were injected 4 weeks later with 1 × 1012 vg per mouse of 
dsAAV7/HBV-S1, dsAAV8/HBV-S1, or dsAAV9/HBV-S1. Serum 
HBV titers were measured to evaluate the RNAi efficacy of the 
second dsAAV/HBV-S1 injection. As shown in Figure 5, pretreat-
ment with dsAAV8/GL2 completely abrogated the RNAi effect of a 
subsequent injection of dsAAV8/HBV-S1, serum HBV DNA levels 
at all time points being comparable to those of the control saline 
group. In contrast, dsAAV7/HBV-S1 and dsAAV9/HBV-S1 were 
equally potent at reducing HBV titers in mice previously injected 
with dsAAV8 vector, the reduction being almost as good as that in 
naive mice (Figure 2b). These data clearly show that dsAAV7 and 
dsAAV9 transduction was not affected by the presence of an anti-
AAV8 humoral immune response.
Then we investigated whether injection of a second dsAAV 
vector of a different serotype could prolong RNAi-mediated HBV 
suppression. Figure 6a and b show results from two indepen-
dent experiments on, respectively, two and three mice. In both 
experiments, the initial treatment of the HBV transgenic mice 
with 1 × 1012 vg per mouse of dsAAV8/HBV-S1 led to a rapid and 
significant decrease in serum HBV titer, with a maximal reduc-
tion of between 260- and 3,570-fold. The RNAi inhibitory effect 
then gradually diminished, and, by week 56, the titer rose to a 
level approaching the pretreatment titer in all mice except mouse 
#1301 (Figure 6b), which still showed an eightfold reduction. 
In  experiment 1, when a second injection of dsAAV9/HBV-S1 at a 
dose of 3.3 × 1013 vg/kg was given 60 weeks after the initial treat-
ment, up to 10,000-fold reduction in serum HBV titer was seen 
3–4 weeks later in both mice (#1318 and #1340) (Figure 6a). In 
experiment 2, a second injection of the same dose of dsAAV9/
HBV-S1 at week 62 led to a 550-, 670-, and 2,500-fold reduction 
in HBV DNA in mouse #1316, #1301, and #1325, respectively 
(Figure 6b). Interestingly, we found that the suppressive effect on 
the HBV titer after the second vector injection decreased much 
faster than that caused by the first injection. For example, in mouse 
#1318 in experiment 1, after the second injection, HBV suppres-
sion rebounded from >2,000-fold (week 65) to <200-fold (week 
69) within 4 weeks, whereas the first dsAAV treatment resulted in 
>250-fold inhibition for at least 20 weeks in the same mouse.
We designed experiments to investigate the mechanisms lead-
ing to the rapid HBV rebound after the second dsAAV RNAi 
treatment. First, we ruled out the possibility of selection of shRNA-
resistant HBV mutants. The genome of HBV isolates (N = 3) from 
the long-term treated animals were sequenced and found that all 
viruses maintained the wild-type HBV-S1 target sequence. Another 
possible cause of the rapid HBV rebound might be the presence 
of AAV-specific T-cell responses, which might be induced by the 
initial dsAAV8 treatment and boosted by the second dsAAV9 
vector. A previous clinical study showed that AAV-induced T cells 
could cause damage to the transduced hepatocytes, therefore 
leading to reduced level and duration of transgene expression.29 
To exclude possible immune interference from the previous AAV8 
treatment, we designed an experiment by injecting dsAAV9/
HBV-S1 in untreated ICR/HBV mice of the same age as those 
receiving the second injection in the multiple dsAAV treatment 
experiments described above (Figure 6), and also included 6– 
8-week-old mice as controls. As shown in Figure 7a, injection of 
dsAAV9/HBV-S1 resulted in a similar inhibitory effect in the first 
4 weeks in both aged and young mice. However, HBV suppression 
10−2
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Figure 5 Preimmunization with double-stranded adeno-associated 
virus 2/8 (dsAAV2/8) does not block the anti-HBV effect of other 
dsAAV serotypes expressing HBV-s1 small hairpin rnA (shrnA). 
Hepatitis B virus (HBV) transgenic mice were initially intravenously 
injected with 1 × 1012 vector genomes (vg) per mouse of dsAAV2/8/
GL2, then, 4 weeks later, were randomly grouped and received a second 
injection of 1 × 1012 vg per mouse of dsAAV7, dsAAV8, or dsAAV9 vector 
expressing HBV-S1 shRNA. Mice injected with saline served as controls. 
Serum HBV titers at the indicated time points after the second injection 
were determined and are presented as a percentage of the pretreatment 
titer for the group (mean ± SD; n = 3).
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in the aged mice rapidly decreased from week 5 and by week 8 
HBV titers in all mice of this group returned to the pretreatment 
level (Figure 7a). By contrast, the RNAi silencing effect in young 
HBV transgenic mice persisted stably within the 8-week observa-
tion period (Figure 7a). Southern blot analysis showed that the 
amount of AAV vector DNA in the liver of aged mice decreased 
by an average of 6.5-fold within 8 weeks, but remained relatively 
stable in the young mice (Figure 7b, upper panel). Accordingly, 
the antisense strand of HBV-S1 shRNA also decreased much more 
rapidly in the aged mice than that in the young mice (Figure 7b, 
lower panel). Expression levels of the control miRNA-122 and 5S 
rRNA remained stable in both young and aged mice. Together, 
these results suggest that the rapid loss of RNAi effects after the 
secondary dsAAV injection was independent of dsAAV8 pretreat-
ment; instead, this phenomenon is closely related to the age of the 
treated animals.
dIscussIon
The main goal of this study was to develop and improve novel 
RNAi-based gene therapies for the treatment of chronic HBV 
infection, which responds poorly to current antiviral regimens.6,30 
We used ICR/HBV transgenic mice as a model system in which 
the majority of hepatocytes constitutively produce large amount 
of HBV proteins and viral particles, which thus represent a more 
clinically relevant and challenging target for antiviral treatment. 
Our previous study showed that the shRNA-expressing dsAAV8 
vector had a marked anti-HBV effect in these transgenic mice.23 
However, the effect weakened with time, which might probably 
in part due to a gradual decline in AAV copy number in the 
 transduced hepatocytes. Multiple administrations of serologically 
non-cross-reactive AAV serotypes represent an attractive approach 
to prolong the RNAi-mediated anti-HBV effect. In this report, 
we compared the three hepatotropic dsAAV vectors, dsAAV7, 
dsAAV8, and dsAAV9, for their in vivo transduction efficiency 
and ability to suppress HBV replication and gene expression in the 
transgenic mouse model. Our results showed that all three vectors 
infected a significant number of hepatocytes and caused profound 
suppression of serum and liver HBV, with dsAAV8 vector having 
the greatest inhibitory effect. More importantly, we showed that 
a significant anti-HBV effect could be achieved by readministra-
tion of a serologically distinct dsAAV vector carrying the same 
shRNA. Thus, by combining the power of the RNAi silencing 
effect and the strategy of multiple dsAAV injections, a maximum 
anti-HBV effect could be achieved and maintained, which might 
provide great benefit for chronic HBV patients.
Of the three hepatotropic dsAAV vectors tested, dsAAV8 
consistently had the best RNAi-mediated anti-HBV effect at 
all time points analyzed. For example, at 2 weeks after dsAAV 
administration (Figure 2a), dsAAV8/HBV-S1 reduced the serum 
HBV titer by an average of 2,380-fold compared to the average 
710- and 800-fold reduction by dsAAV7/HBV-S1 and dsAAV9/
HBV-S1, respectively. dsAAV8/HBV-S1 also caused the largest 
decrease in liver HBV RNA and DNA levels (Figure 3a and b). 
The superior anti-HBV effect of the dsAAV8 vector was because 
of its higher liver transduction efficiency of 65% compared to the 
values of 34 or 50% for the dsAAV7 or dsAAV9 vector, respectively 
(Figure 1a), which might be ascribed to the rapid uncoating of the 
AAV8 capsid after entry into hepatocytes.31,32 These characteris-
tics allowed the dsAAV8 vector to deliver the highest amounts of 
AAV genome in the liver (an average of 25 copies per cell versus 
7.6 and 13 copies per cell for dsAAV7 and dsAAV9, respectively) 
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Figure 6 effect of multiple administration of double-stranded adeno- 
associated virus (dsAAV) vectors expressing HBV-s1 small hairpin 
rnA in transgenic mice. (a,b) The data for two independent experi-
ments on (a) two mice or (b) three mice. Hepatitis B virus (HBV) trans-
genic mice (6–8-weeks old) were injected with 1 × 1012 vector genomes 
(vg) per mouse of dsAAV2/8/HBV-S1, then, (a) 60 or (b) 62 weeks later, 
were re-injected with dsAAV2/9/HBV-S1 at a dose of 3.3 × 1013 vg/kg. 
Serum HBV titers at the indicated time points were measured and are pre-
sented as a percentage of the pretreatment titer for the same mouse.
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Figure7 Hepatitis B virus (HBV) suppression by double-stranded 
adeno-associated virus 9 (dsAAV9)/HBV-s1 in young and aged trans-
genic mice. HBV transgenic mice at the age of 6–8-week or 14-month 
old were injected with 3.3 × 1013 vg/kg of dsAAV9/HBV-S1. (a) Serum 
HBV titers at the indicated time points after injection were measured 
and presented as described in the legend of Figure 2. (b) Total liver 
DNA and RNA were collected at the indicated time points. Southern and 
northern blots were used to analyze the amount of AAV DNA (upper 
panel) and antisense HBV-S1 shRNA, miR-122, and 5S rRNA (lower 
panel), respectively.
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HBV-S1 shRNA (1.43- and 1.35-fold higher than that produced 
by dsAAV7 and dsAAV9, respectively) (Figure 4b). Interestingly, 
the dsAAV7 vector was as effective as dsAAV9 in inhibiting HBV 
replication and gene expression (Figures 2 and 3), but the liver 
transduction rate for dsAAV7 (34%) was significantly lower than 
that achieved using dsAAV9 (50%) (Figure 1). One major differ-
ence between dsAAV7 and dsAAV9 in liver transduction was that 
dsAAV7 transduction was essentially restricted to the centrilobu-
lar hepatocytes (Figure 1a), whereas dsAAV9 transduction was 
relatively uniform throughout the liver section. The preferential 
gene delivery to the centrilobular hepatocytes by the dsAAV7 
vector might help increase its overall anti-HBV effect, because 
HBV replication is mainly restricted to the cytoplasm of these 
centrilobular hepatocytes in the transgenic mouse model.23,33
In this study (Figure 2) and in our previous report,23 we 
showed that a single treatment with dsAAV vectors expressing 
HBV-S1 shRNA dramatically decreased serum and liver HBV 
within 1 month, but the RNAi effect gradually decreased with time. 
This result conflicts with those in other reports, which showed 
that, regardless of vector genome structure (single-stranded or 
double-stranded), AAV vectors, particularly the AAV8 serotype, 
are able to produce and sustain high levels of transgene expression 
in the liver for months to years in various animal models.26,34,35 
The decline in the RNAi effect in our studies was, at least in part, 
due to the decrease in AAV genome copy number in the liver.23 
It is known from studies employing partial hepatectomy that 
the majority of the injected AAV vector in hepatocytes remains 
episomal (>90%), rather than becoming integrated into the hepa-
tocyte chromosome.36 Thus, the amount of AAV DNA, as well as 
the level of transgene expression, decreases more rapidly during 
liver growth or hepatocyte regeneration.37,38 Our unpublished 
results and the results of several other studies2,39,40 show that mice 
carrying partial or complete HBV genomes are prone to sponta-
neous or exogenous hepatic damage because of the accumulation 
of high levels of HBV proteins and viral particles. The enhanced 
hepatocyte damage in HBV transgenic mice would theoretically 
induce regenerative stimuli and subsequently compensatory liver 
proliferation. Thus, the more rapid decrease in AAV DNA in HBV 
transgenic mice might be partially due to a higher liver turnover 
rate in this animal model.
Multiple AAV administration represents an attractive app-
roach to prolonging the RNAi-mediated anti-HBV effect in the 
HBV transgenic mouse model. Host humoral immune responses 
directed against the AAV capsid protein induced by previous injec-
tions might prevent subsequent treatment with AAV vectors with 
the same capsid.41,42 To overcome this problem, several groups 
have demonstrated that efficient gene delivery can be achieved 
in the presence of preexisting immunity using non-cross-reactive 
AAV serotypes. 26,27,43 In this study, we used animal experiments to 
examine whether the RNAi effect could be induced by a second 
injection with a different dsAAV vector. In an in vivo cross- 
administration experiment, we showed that anti-AAV8 immunity 
completely blocked the dsAAV8/HBV-S1-mediated anti-HBV 
activity, but did not interfere with the effect of dsAAV7/HBV-S1 
or dsAAV9/HBV-S1 (Figure 5). Most importantly, we showed that 
injection of dsAAV9/HBV-S1 into dsAAV8/HBV-S1-pretreated 
transgenic mice at a time when the HBV titer had returned to the 
pretreatment level resulted in a similar decrease in serum HBV 
DNA to that seen in naive mice treated with the same dsAAV9 
vector (Figure 6). These results provide evidence that the sequen-
tial use of different dsAAV serotypes can prolong the RNAi-
mediated HBV suppression. The three hepatotropic AAV vectors 
are highly homologous in capsid amino acid composition (88% 
homology between AAV8 and AAV7 and 85% between AAV8 and 
AAV9).19,24 The lack of cross-reactivity between these AAV vectors 
is probably due to the presence of several variable regions in the 
capsid protein that are responsible for receptor binding and anti-
body recognition.44 Multiple administration of different dsAAV 
serotypes carrying a different shRNA also provides a means 
against RNAi-selected mutant viruses, which escape the original 
RNAi inhibition by mutating the target sequence after prolonged 
treatment.13,45,46
Interestingly, in the multiple dsAAV treatment study we found 
that the suppressive effect of RNAi after the second dsAAV injec-
tion decreased much faster than that caused by the first injection 
(Figure 6a and b). The quick HBV rebound was not due to selec-
tion of RNAi-resistant HBV mutants, because sequencing HBV 
isolates from the long-term treated animals revealed no mutation 
in the HBV-S1 target sequence. The unstable RNAi effect after the 
second injection was neither related to the previous dsAAV treat-
ment. This is proved by treating naive HBV mice, which never 
encountered dsAAV before, with the same amount of dsAAV9, 
and showed that by 8 week after injection HBV quickly rebound 
to the pretreatment level in the aged but not the young mice 
(Figure 7a). These results suggest the rapid loss of RNAi effects was 
closely related to the age of the mice when receiving dsAAV treat-
ment. The AAV dilution effect caused by hepatocyte regeneration 
as discussed above might also explain the unstable RNAi effects 
observed in the aged mice, which presumably experience higher 
levels of liver damage and enhanced proliferation than younger 
mice (Figures 6 and 7). Interestingly, after dsAAV9/HBV-S1 
injection we observed an even faster HBV rebound in the aged but 
previously untreated mice than in mice that received RNAi treat-
ment in the young age. In the latter group, the long-term HBV 
suppression by the first RNAi therapy presumably could alleviate 
liver damage in the transgenic mice, and thus these animals might 
have slower hepatocyte regeneration rate than those in the former 
group. We are currently investigating the hepatocyte turnover rate 
in RNAi-treated and untreated HBV transgenic mice to further 
clarify this issue.
A recent report by Grimm et al.28 showed that effective anti-
HBV RNAi therapy using a similar self-complementary AAV8 
vector was associated with dose-dependent liver injury and even 
animal death. This toxic effect was probably due to overexpression 
of shRNA, which might interfere with endogenous microRNA 
processing and functionality. However, in our study, none of the 
animals receiving long-term RNAi therapy showed liver  damage 
(normal alanine aminotransferase levels, data not shown) or 
mortality, even the AAV dosage being increased to 3 × 1012 vg per 
mouse (data not shown), three times higher than the reported 
toxic doses in Grimm’s study. Furthermore, analysis of microRNA 
expression in our dsAAV-treated mice showed that levels of 
endogenous microRNA-122 in the liver were not different from 
those in the control animals (Figure 4b, lower panel). One of the 
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main differences between the study of Grimm et al. and our own 
is promoter usage, as the H1 promoter was used in our system 
and the U6 promoter in Grimm’s study. The U6 promoter–driven 
shRNA has been reported to cause cell death by apoptosis, and 
toxicity was prevented by replacing the U6 promoter with the H1 
promoter.47 We are currently investigating whether the U6 pro-
moter is the major cause of toxicity by replacing the H1 promoter 
in our AAV vector with the U6 promoter.
In summary, our study underscores the potential of the 
 multiple administrations of different dsAAV serotypes in inducing 
persistent RNAi suppression. Long-term HBV suppression can be 
achieved in the absence of any obvious RNAi- or vector- associated 
toxicity. We believe this approach could be further developed to 
become a convenient and effective treatment for keeping the 
HBV titer below a certain threshold, which might be beneficial in 
 protecting chronic HBV patients from developing progressive liver 
diseases.
MAterIAls And MetHods
dsAAV vector preparation. Plasmids pAAVEMBL-CMV-GFP and pAA-
VEMBL-CB-GFP containing the GFP transgene driven, respectively, 
by the cytomegalovirus (CMV) promoter or the chicken β-actin pro-
moter have been described elsewhere.48 These plasmids were designed 
to  produce dsAAV genomes by introducing a deletion of the D-sequence 
and terminal resolution site into one end of the AAV2 inverted termi-
nal repeat.48 Construction of pAAVEMBL/HBV-S1 and pAAVEMBL/
GL2, which encode, respectively, a HBV- or a firefly luciferase– specific 
shRNA transcript under the control of the H1 promoter, has been 
described previously.23 The CMV promoter of the original pAAVEMBL- 
CMV-GFP plasmid was deleted, but the GFP coding sequence was 
preserved to maintain the size of the dsAAV genome at ~1.5 kb for dsAAV 
packaging. The pseudotyped dsAAV7, dsAAV8, and dsAAV9 vectors were 
generated by cross-packaging the pAAVEMBL plasmid with plasmids 
containing each individual serotype-specific capsid gene as described 
previously.37 The recombinant dsAAV vectors were purified by two 
rounds of CsCl sedimentation. The physical vector titers were assessed 
by quantitative PCR amplification of DNase-protected particles using 
SYBR Green reaction mix (Roche Diagnostics, Mannheim, Germany) 
and primers (sense: 5′-ACGTCTATATCATGGCCG-3′; antisense: 
5′-TGTGATCGCGTTCTC-3′) specific for the common GFP sequence 
presenting in all pAAVEMBL plasmids.
Animals and vector administration. Wild-type ICR mice (purchased from 
BioLASCO, Ilan, Taiwan) and HBV transgenic mice (line Tg[HBV1.3]24-3), 
which contain a 1.3-times overlength HBV genome of the ayw subtype on 
the ICR background,23 were used. This HBV transgenic mouse line pro-
duces high levels of HBV replicative DNA and all forms of viral mRNAs 
and proteins in the liver, which mimics the situation in progressive chronic 
HBV-infected patients. To measure the liver transduction rate, wild-type 
ICR mice were IV injected with 1 × 1012 vg per mouse (or ~3.3 × 1013 vg/kg) 
of different dsAAV serotype vectors expressing GFP driven by the CB 
promoter, then, 3 weeks later, liver fragments were isolated for GFP 
analysis. To evaluate the RNAi-mediated anti-HBV effect, 6–8-week- or 
14-month-old male HBV transgenic mice with serum HBV titers of 
>5 × 107 genome copies/ml were IV injected with 1 × 1012 vg per mouse 
(young mice) or 3.3 × 1013 vg/kg (aged mice) of different dsAAV serotype 
vectors encoding HBV-S1 or GL2 shRNAs, and serum and liver samples 
were collected at different times for analysis. For cross-administration 
experiments, HBV transgenic mice were IV injected with 1 × 1012 vg of 
dsAAV8/GL2, then, 4 weeks later, with 1 × 1012 vg per mouse of dsAAV7/
HBV-S1, dsAAV8/HBV-S1, or dsAAV9/HBV-S1. To investigate the RNAi 
effect of multiple AAV injections, HBV transgenic mice were IV injected 
with 1 × 1012 vg per mouse of dsAAV8/HBV-S1, then with dsAAV9/
HBV-S1 60–62 weeks later. The amount of dsAAV vector used in the 
second injection was increased to keep the final dsAAV dose at 3.3 × 
1013 vg/kg. All animals were housed in a specific pathogen-free envi-
ronment in the animal facility of the Institute of Biomedical Sciences, 
Academia Sinica. All experimental procedures were in compliance with 
Academia Sinica IACUS and Council of Agriculture Guidebook for the 
Care and Use of Laboratory Animals.
Detection of GFP expression. To detect GFP expression, liver fragments 
were embedded in optimal cutting temperature medium and cryosections 
(5 μm) were mounted on positively charged slides and examined by fluo-
rescence microscopy. For quantitative analysis of GFP intensity, at least 
5 observation fields per section were randomly photographed with constant 
exposure conditions to keep the data comparable. The average intensity 
and the GFP-positive area were analyzed using Image-Pro Plus software 
(version 6.2; Media Cybernetics, Atlanta, GA). The percentage of the total 
area containing GFP-positive cells was calculated as (GFP-positive area/
total liver area) × 100%.
Analysis of HBV DNA and RNA. Serum samples were collected at dif-
ferent time points and DNA were extracted to measure the HBV viral 
load. A sensitive hybridization probe–based real-time PCR was used 
to measure the HBV titer. The sequences of the primers were: forward 
primer (HBV1.3fw), 5′-CTCCACCAATCGCCAGTC-3′; reverse primer 
(HBV1.3as); 5′-ATCCTCGAGAAGATTGACGATAAT-3′; 3′-fluorescein 
(fam)-labeled donor probe, 5′-CATGGCCTGAGGATGAGTGTTTCT 
CA-3′; and 5′-Red640-labeled acceptor probe, 5′-AGGTGGAGACAGC 
GGGGTAGG-3′ (LightCycler FastStart; Roche Diagnostics). Plasmid 
pHBV1.3 of tenfold dilutions (1.33 × 103 to 1.33 × 109 copies/ml) was used 
to generate a standard curve in parallel PCRs. The liver fragments were 
mechanically ground in liquid nitrogen and resuspended in lysis buffer 
(100 mmol/l NaCl, 10 mmol/l Tris, pH 7.4, 1 mmol/l EDTA, 0.5% sodium 
dodecyl sulfate, supplemented with 100 μg/ml of proteinase K and 100 μg/
ml RNaseA) at 37 °C for 12–16 hours to digest tissues. Total DNA were 
extracted using phenol/chloroform and analyzed by Southern blot analysis 
of 10 μg of DNA digested with HindIII, which does not cut within the HBV 
transgene. The samples were separated on an agarose gel, transferred to a 
nylon membrane (Amersham Biosciences, Piscataway, NJ), and hybridized 
with a 32P-labeled HBV-specific DNA probe (Rediprime II, GE Healthcare, 
Piscataway, NJ). Signals were developed using phosphor screens and ana-
lyzed using ImageQuant software (Molecular Dynamics, Sunnyvale, CA). 
Total RNA was isolated using TRIZOL reagent according to the manufac-
turer’s instructions (Invitrogen, Carlsbad, CA). For northern blot analysis, 
10 μg of total liver RNA was separated by electrophoresis on a 1% agarose 
formaldehyde gel and transferred to a nylon membrane, then the blot was 
hybridized with a biotin-labeled HBV or glyceraldehyde 3-phosphate dehy-
drogenase probe which were prepared with North2South Biotin Random 
Prime DNA Labeling Kit (Pierce, Rockford, IL). Signals were visualized by 
chemiluminescence (Pierce) and analyzed using ImageQuant software.
Detection of AAV DNA. To detect AAV DNA in the liver, 10 μg of total 
liver DNA, digested with HindIII and XbaI to release a 1.05-kb frag-
ment, was subjected to Southern blot analysis. The blot was probed with a 
32P-labeled DNA fragment corresponding to the GFP coding sequence, 
which is present in all pAAVEMBL vectors used in this study. Amounts 
of the pAAVEMBL plasmid corresponding to 0.6–15 copies per diploid 
genome were used as standards. Southern blot hybridization and quantifi-
cation of signals were performed as described in the earlier section.
Small RNA northern blot analysis. For small RNA northern blot  analysis, 
30 μg of total liver RNA from dsAAV-treated animals was separated on 
a 15% polyacrylamide–urea gel, transferred to a nylon membrane, and 
hybridized to 32P-labeled oligonucleotides (19 nt) corresponding to the 
antisense strand of the HBV-S1 shRNA, microRNA-122, or 5S rRNA. Equal 
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RNA loading was assessed by ethidium bromide staining. ImageQuant 
software was used to quantify small RNA signals as described above.
suPPleMentAry MAterIAl
Figure S1. Serologic cross-reactivity of the different dsAAV 
serotypes.
Materials and Methods. Anti-AAV neutralization assay.
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